Frontiers in Anti-Infective Drug Discovery is a valuable resource for pharmaceutical scientists and post-graduate students seeking updated and critically important information for developing clinical trials and devising research plans in this field. The tenth volume of this series features 4 reviews on the following topics: -Pharmacotherapy of Posterior Segment Ocular Infections -Discovery and Development of Antimalarial Drug-Resistance Reversal Agents -Omics Technologies and Anti-Infective Drug Discovery -Possible Cutaneous Adverse Effects of Anti-Infective Vaccinations

In this third year of the SARS-CoV-2 pandemic responsible for COVD-19 and related diseases worldwide, the scientific studies and reviews focused on this virus and its variants are still crucial. The third volume of the Coronaviruses series brings together some essential data regarding the origin, pathology and chemotherapeutic drugs to treat coronavirus infections. Contributions are written by experienced researchers with the goal of updating medical researchers and clinicians dealing with COVID-19 patients. It presents seven chapters covering a range of topics: (1) bat coronaviruses in the world, (2) hospital challenges during the COVID-19 pandemic, (3) the pro-inflammatory and thrombotic manifestations and the therapeutic options of Covid-19, (4) the common and rare dermatologic manifestations registered in COVID-19 patients, (5) the circulating biomarkers of cardiopulmonary disturbances in COVID-19, and (6) the aspects of pathology and pathogenesis of coronavirus infection

This compendium represents a set of guides to understanding the challenging scientific, epidemiological, clinical, social, and economic phenomenon that is represented by the COVID-19 pandemic. The book explains the mathematical modeling of COVID-19 infection, with emphasis on traditional epidemiological principles. It represents a rigorous, comprehensive and multidisciplinary approach to a complex phenomenon. The chapters take into account the knowledge arising from different disciplines (epidemiology, pathophysiology, immunology, medicine, biology, vaccine development, etc.). It also covers COVID-19 data analysis, giving the reader a perspective of statistics and data science, and includes a discussion about social and economic issues of the pandemic. Each chapter is devoted to a specific topic, and is contributed by experts in epidemiology. Because of its multidisciplinary nature, this book is intended as a reference on mathematical models and basic immunotherapy for COVID-19 for a broad community of readers, from scholars who have scientific training, to general readers who have an interest in the disease.

Coronavirus disease 2019 (COVID-19) has affected millions of people across the world. Clinicians and scientists across the globe need all the information of this pandemic on one platform. Today, it is also necessary to find out the association of COVID-19 with various medical comorbidities, and its effect on vulnerable populations that require special medical attention. This information will be helpful for the management of COVID-19. COVID-19: Effects in Comorbidities and Special Populations is a concise and visual reference for information about this viral disease and its relationship with different medical conditions. The book provides comprehensive knowledge covering COVID-19 comorbidities (for example, CVD, Diabetes, lung diseases, etc.), and the incidence in specific groups (for example, children and the elderly). Chapters outline the features and the management of the disease in specific conditions. Key Features: - 12 chapters covering several aspects of COVID-19 management, making this a perfect text book for virologist and medical students - Focused and structured description of different effects of COVID-19 in specific patient groups - Multiple tables and figures which summarizes and highlight important points - Multiple choice questions for learners - Detailed list of references, abbreviations and symbols This book is an essential reference for practicing and training virologists, pulmonologists, medical students and scientists working in research labs, pharmaceutical and biotechnology industries in connection with the control of COVID-19 infection.

This update on SARS-CoV-2 focuses on basic knowledge about the virus and COVID-19 treatment. Chapters present basic information about the disease and its treatment. The virology, epidemiology, etiology, and damage response framework of SARS-CoV-2 are also discussed in detail. The book also covers recent topics of interest to pharmacology scholars such as the immunopathogenesis of SARS-CoV2, nanotechnology, repurposed drug treatments, COVID-19 vaccines, and phytomedicine for COVID-19 therapeutics. Readers in pharmacology, virology and medicine will find the book a simple, yet informative update on SARS-CoV-2 and COVID-19 treatment.

An Epidemiological Update on COVID-19 brings recent findings about the pandemic to the forefront. The reference is a compilation of eleven chapters contributed by expert scholars in epidemiology and medicine that cover topics of interest to anyone interested in COVID-19 monitoring and response measures. The topics also indicate some clinical areas of interest to COVID-19 researchers that have received attention due to the pandemic. It covers basic knowledge about respiratory conditions associated with SARS-CoV-2 infection and COVID-19 epidemiology. These topics are complemented with chapters detailing the symptoms and biochemical mechanisms of novel coronavirus infections intended for readers with an advanced level of understanding of life sciences and medicine. Special topics such as the immune response to Sars-CoV-2, and, recombinant drugs for COVID-19, are also covered in this book. Each chapter is organized in a reader-friendly format and includes a list of references.

Frontiers in Clinical Drug Research : Anti - infectives is a book series that brings updated reviews to readers interested in learning about advances in the development of pharmaceutical agents for the treatment of infectious diseases. The scope of the book series covers a range of topics including the chemistry, pharmacology, molecular biology and biochemistry of natural and synthetic drugs employed in the treatment of infectious diseases. Reviews in this series also include research on multi drug resistance and pre-clinical / clinical findings on novel antibiotics, vaccines, antifungal agents and antitubercular agents. Frontiers in Clinical Drug Research – Anti infectives is a valuable resource for pharmaceutical scientists and postgraduate students seeking updated and critically important information for developing clinical trials and devising research plans in the field of anti infective drug discovery and epidemiology. The eighth volume of this series presents comprehensive reviews of interest to readers interested in the treatment of inflammatory diseases, new antiviral agents and strategies, specific antiprotozoal drugs that work against leishmania and helminths, and a study on potential agents against American foulbrood in honey bees. The 7 reviews included in this volume are: - Monoclonal antibodies as therapeutic agents for inflammatory diseases - Pharmacotherapy of emerging antiviral agents - Antiviral activity of vitamin D and COVID-19: current understanding - Anti-infectives to combat leishmaniasis - Anthelmintic drug discovery: current situation and future perspectives - Therapeutic targets for emerging Zika virus infection and vaccines in clinical trials - Agro-industrial waste: new source of raw material for the control of American foulbrood in honey bees

Anti-infective agents are a distinct class of pharmacologically important molecules that have served mankind in different capacities to combat life-threatening pathological conditions. They include antibacterial, antifungal, antiviral, antituberculosis, antimalarial, and urinary anti-infective agents. However, evolutionary changes, adaptations, and the development of new strains of pathogenic microorganisms have reduced the therapeutic efficacy of existing drugs, thus, limiting their clinical utility over the years. Frontiers in Anti-Infective Agents Volume 6 is a collection of notable research efforts, successful anti-infective drug development programs, and a comprehensive overview of successful and unsuccessful clinical trials conducted in this domain. This volume continues from the last one with interesting reviews on 1) “Reverse Vaccinology” for vaccination design using computational data to identify vaccine targets, 2) leptospirosis, 3) phage therapy for bacterial infections, 4) quorum sensing inhibitors from natural products, and 5) nitrogen and oxygen-based heterocyclic compounds that can act as anti-infective agents. The volume, therefore, covers a range of frontier topics on anti-infective research and development. This compilation is a timely reference for postgraduate scholars and researchers seeking updates in specific areas of anti-infective drug development. Allied healthcare professionals (clinical and public healthcare professionals) can also benefit from the information presented within.

In this book volume-2 proposal has been classified into Part IV: Models for SARS-CoV-2 and Part V: Treatment Strategies for SARS-CoV-2. With the emergence of new coronavirus variants, epidemiology, different host tropism permits a thorough analysis of their evolution and acquired adaptability to their host which need different animal models and treatment approaches. No studies are complete without animal models closely related to human physiology to replicate the disease and observe the pathology conditions as in human cases. Such animal models play a vital role in virus pathogenesis and prepare a therapeutic immune response. Here describe bio-engineered transgenic mouse model inserting with specific genes, or CRISPR-Case9 gene-editing tool has been used previously for SARS-CoV and MERS-CoV. The chapter will deal with culture techniques or cell lines for COVID-19—also histopathology of COVID-19, essential proteins that up or down-regulate SARS-CoV-2. The last chapter of this part will describe other diseases having similar signs and symptoms and their differentiation. There is no specific treatment available to date, just symptomatic therapy. However, scientists will elucidate effective antiviral drugs in clinical trials, phytochemicals, photomedicine such as ultraviolet A & B, homemade remedies, blood plasma transfusion, stem cell therapy, and computational approaches in vivo and in vitro trials. This book will appear as a baseline for academicians, scientists, and health professionals as still, research is going to overcome this outbreak of COVID-19, the novelty of best animal models, and find an effective treatment. However, just a single book proposal like this wouldn't have flourished without enthusiasm and determined publishers' and investigators' strength to take time from their busy schedule and subsidize on time. We thank the whole investigators who contributed, directly and indirectly, to bring it to reality.